Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - dorzolamidum, timololum - co-dorzolamid-mepha 2% / 0.5%.augentropfen - dorzolamidum 20 mg ut dorzolamidi hydrochloridum, timololum 5 mg ut timololi maleas, conserv.: benzalkonii chloridum, aqua ad iniectabilia q.s. ad solutionem pro 1 ml. - le glaucome - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - telmisartanum, hydrochlorothiazidum - co-telmisartan spirig hc 80/25 mg tabletten - telmisartanum 80 mg, hydrochlorothiazidum 25 mg, magnesii stearas, kalii hydroxidum corresp. kalium 6.37 mg, megluminum, povidonum k 29-32, carboxymethylamylum natricum a corresp. natrium 1.66 mg, cellulosum microcristallinum, mannitolum, pro compresso. - antihypertensivum - synthetika

Union européenne - français - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - cellule précurseur leucémie lymphoblastique - lymphome - agents antinéoplasiques - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Canada - français - Health Canada

novartis pharmaceuticals canada inc - inclisiran (inclisiran sodique) - solution - 284mg - inclisiran (inclisiran sodique) 284mg

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - enalaprili malèas, hydrochlorothiazidum - comprimés - enalaprili maleas 20 mg, hydrochlorothiazidum 12.5 mg, natrii hydrogenocarbonas corresp. natrium 2.79 mg, lactosum monohydricum 89.6 mg, calcii hydrogenophosphas dihydricus, maydis amylum, talcum, magnesii stearas, pro compresso. - antihypertensivum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - amoxicillinum anhydricum, l'acide clavulanicum - poudre pour suspension buvable - amoxicillinum anhydricum 400 mg ut amoxicillinum trihydricum, acidum clavulanicum 57 mg ut kalii clavulanas, silica colloidalis anhydrica, xanthani gummi, crospovidonum, carmellosum natricum, aspartamum 16.64 mg, aromatica (erdbeer) cum alcohol benzylicus et propylenglycolum ad pulverem corresp. suspensio reconstituta 5 ml corresp. natrium max. 7.3 mg. - les maladies infectieuses - synthetika

Union européenne - français - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - agents de modification des lipides - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

organon france - énalapril (maléate d') 20 mg; hydrochlorothiazide 12 - comprimé - 20 mg - pour un comprimé > énalapril (maléate d' 20 mg > hydrochlorothiazide 12,5 mg - inhibiteurs de l'enzyme de conversion et diuretiques - classe pharmacothérapeutique : inhibiteurs de l'enzyme de conversion et diuretiques - code atc : c09ba02.ce médicament est un antihypertenseur contenant 2 principes actifs, dont un diurétique, l’autre principe actif appartenant au groupe des inhibiteurs de l’enzyme de conversion.ce médicament est préconisé dans le traitement de l’hypertension artérielle, en cas de contrôle insuffisant sous un seul médicament (inhibiteur de l’enzyme de conversion).

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - l'acide clavulanicum, amoxicillinum anhydricum - comprimés pelliculés - acidum clavulanicum 125 mg ut kalii clavulanas, amoxicillinum anhydricum 500 mg ut amoxicillinum trihydricum, magnesii stearas, talcum, povidonum k 25, cellulosum microcristallinum, carmellosum natricum conexum, Überzug: triethylis citras, ethylcellulosum, natrii laurilsulfas, alcohol cetylicus, hypromellosum, talcum, e 171, pro compresso obducto corresp. natrium max. 9 mg. - les maladies infectieuses - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - amoxicillinum anhydricum, l'acide clavulanicum - poudre pour la préparation d'une suspension buvable - amoxicillinum anhydricum 125 mg ut amoxicillinum trihydricum, acidum clavulanicum 31.25 mg ut kalii clavulanas, acidum citricum, natrii citras anhydricus, talcum, guari gummi, silicii dioxidum praecipitatum, aromatica (zitrone, pfirsich-aprikose, orange) cum sorbitolum, glucosum, propylenglycolum, ethanolum, e 220 et alcohol benzylicus, aspartamum 8.5 mg, ad pulverem corresp., suspensio reconstituta 5 ml corresp. natrium 4.375 mg. - les maladies infectieuses - synthetika